168 related articles for article (PubMed ID: 32445869)
1. Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer.
Bailly C; Vergoten G
Biochem Pharmacol; 2020 Aug; 178():114042. PubMed ID: 32445869
[TBL] [Abstract][Full Text] [Related]
2. N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.
Bailly C; Vergoten G
Comput Biol Chem; 2020 Oct; 88():107362. PubMed ID: 32871472
[TBL] [Abstract][Full Text] [Related]
3. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
[TBL] [Abstract][Full Text] [Related]
4. Protein homodimer sequestration with small molecules: Focus on PD-L1.
Bailly C; Vergoten G
Biochem Pharmacol; 2020 Apr; 174():113821. PubMed ID: 31972166
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization.
Guo Y; Jin Y; Wang B; Liu B
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946261
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.
Zhu P; Zhang J; Yang Y; Wang L; Zhou J; Zhang H
Mol Divers; 2022 Feb; 26(1):245-264. PubMed ID: 33786726
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.
Ashizawa T; Iizuka A; Tanaka E; Kondou R; Miyata H; Maeda C; Sugino T; Yamaguchi K; Ando T; Ishikawa Y; Ito M; Akiyama Y
Biomed Res; 2019; 40(6):243-250. PubMed ID: 31839668
[TBL] [Abstract][Full Text] [Related]
8. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
[TBL] [Abstract][Full Text] [Related]
9. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach.
Mittal L; Tonk RK; Awasthi A; Asthana S
Arch Biochem Biophys; 2021 Nov; 713():109059. PubMed ID: 34673001
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking study of britannin binding to PD-L1 and related anticancer pseudoguaianolide sesquiterpene lactones.
Vergoten G; Bailly C
J Recept Signal Transduct Res; 2022 Oct; 42(5):454-461. PubMed ID: 34789056
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based screening of programmed death ligand 1 (PD-L1).
Perry E; Mills JJ; Zhao B; Wang F; Sun Q; Christov PP; Tarr JC; Rietz TA; Olejniczak ET; Lee T; Fesik S
Bioorg Med Chem Lett; 2019 Mar; 29(6):786-790. PubMed ID: 30728114
[TBL] [Abstract][Full Text] [Related]
13. Is the Triggering of PD-L1 Dimerization a Potential Mechanism for Food-Derived Small Molecules in Cancer Immunotherapy? A Study by Molecular Dynamics.
Wu X; Wang N; Liang J; Wang B; Jin Y; Liu B; Yang Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674929
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
15. Conjugation of biphenyl groups with poly(ethylene glycol) to enhance inhibitory effects on the PD-1/PD-L1 immune checkpoint interaction.
Kim EH; Ning B; Kawamoto M; Miyatake H; Kobatake E; Ito Y; Akimoto J
J Mater Chem B; 2020 Nov; 8(44):10162-10171. PubMed ID: 33095222
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
Verdura S; Cuyàs E; Cortada E; Brunet J; Lopez-Bonet E; Martin-Castillo B; Bosch-Barrera J; Encinar JA; Menendez JA
Aging (Albany NY); 2020 Jan; 12(1):8-34. PubMed ID: 31901900
[TBL] [Abstract][Full Text] [Related]
17. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.
Ganesan A; Ahmed M; Okoye I; Arutyunova E; Babu D; Turnbull WL; Kundu JK; Shields J; Agopsowicz KC; Xu L; Tabana Y; Srivastava N; Zhang G; Moon TC; Belovodskiy A; Hena M; Kandadai AS; Hosseini SN; Hitt M; Walker J; Smylie M; West FG; Siraki AG; Lemieux MJ; Elahi S; Nieman JA; Tyrrell DL; Houghton M; Barakat K
Sci Rep; 2019 Aug; 9(1):12392. PubMed ID: 31455818
[TBL] [Abstract][Full Text] [Related]
19. Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach.
Paciotti R; Agamennone M; Coletti C; Storchi L
J Comput Aided Mol Des; 2020 Aug; 34(8):897-914. PubMed ID: 32185582
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanism of Food-Derived Polyphenols on PD-L1 Dimerization: A Molecular Dynamics Simulation Study.
Guo Y; Liang J; Liu B; Jin Y
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
